This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Jean-Marie Glantzmann
Introduction
Jean-Marie Glantzmann is a notable inventor based in Michelbach-Le-Bas, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of drug formulations. His work focuses on improving treatment options for patients suffering from Parkinson's disease.
Latest Patents
Jean-Marie Glantzmann holds a patent for a modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester. This patent includes drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056). These drug products are particularly useful in treating patients with Parkinson's disease who exhibit L-dopa induced dyskinesia.
Career Highlights
Jean-Marie Glantzmann is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative drug development and contribute to advancements in medical treatments.
Collaborations
Throughout his career, Jean-Marie has collaborated with notable colleagues such as Bruno Galli and Arnaud Grandeury. These collaborations have played a crucial role in enhancing the research and development of effective drug formulations.
Conclusion
Jean-Marie Glantzmann's contributions to pharmaceutical innovations, particularly in the treatment of Parkinson's disease, highlight his importance as an inventor. His patent for modified release formulations demonstrates his commitment to improving patient care and advancing medical science.